Submission Details
| 510(k) Number | K191288 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | May 13, 2019 |
| Decision Date | September 30, 2021 |
| Days to Decision | 871 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
K191288 is an FDA 510(k) clearance for the Acuitas AMR Gene Panel, a System, Nucleic Acid Amplification Test, Dna, Carbapenem Non-susceptible Gram Negative Organism, Colony (Class II — Special Controls, product code PMY), submitted by Opgen, Inc. (Rockville, US). The FDA issued a Cleared decision on September 30, 2021, 871 days after receiving the submission on May 13, 2019. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.1640.
| 510(k) Number | K191288 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | May 13, 2019 |
| Decision Date | September 30, 2021 |
| Days to Decision | 871 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
| Product Code | PMY — System, Nucleic Acid Amplification Test, Dna, Carbapenem Non-susceptible Gram Negative Organism, Colony |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.1640 |
| Definition | To Detect The Presence Of Genetic Markers Of Antimicrobial Resistance By Testing Isolated Bacterial Colonies Using Nucleic Acid Amplification Technology. |